A5062207538- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immune Cell Function and Interaction
- Eosinophilic Esophagitis
- Mast cells and histamine
- Polyomavirus and related diseases
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Urticaria and Related Conditions
- Kruppel-like factors research
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Parvovirus B19 Infection Studies
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Systemic Sclerosis and Related Diseases
Medical University of Silesia
2016-2025
University of Silesia in Katowice
2016-2025
Górnośląskie Centrum Medyczne
2004-2024
Hospital General Universitario de Alicante Doctor Balmis
2024
Instytut Hematologii i Transfuzjologi
2016
Research Institute for Brown Coal (Czechia)
2005
University of California, Davis
2001
Heinrich Heine University Düsseldorf
1988
Deutsches Diabetes-Zentrum e.V.
1988
Universitäts-Kinderklinik Würzburg
1953-1956
The multicenter retrospective study conducted in 38 centers from 20 countries including 172 adult patients with CNS MM aimed to describe the clinical and pathological characteristics outcomes of multiple myeloma (MM) involving central nervous system (CNS). Univariate multivariate analyses were performed identify prognostic factors for survival. median time diagnosis was 3 years. Thirty‐eight (22%) diagnosed involvement at initial 134 (78%) relapse/progression. Upon MM, 97% received therapy...
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated 551 who received HSCT without ( n = 274) or 277) pretreatment. The overall leukocyte engraftment day 45 was 92% and significantly higher responsive than those had no lost response (94% vs. 85%, p 0.05). 1-year non-relapse mortality 22% significant difference...
Abstract Splenomegaly is the clinical hallmark of myelofibrosis. at time allogeneic hematopoietic cell transplantation (HCT) associated with graft failure and poor function. Strategies to reduce spleen size before HCT especially after Janus kinase (JAK) inhibition represent unmet needs in field. Here, we leveraged a global collaboration investigate safety efficacy splenic irradiation as part platform for patients We included 59 patients, receiving within median 2 weeks (range, 0.9–12 weeks)...
Abstract The role of spleen size and splenectomy for the prediction post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort 1195 patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, was performed 202 (16.9%) its use decreased over time (28.3% 2000‐2009 vs 14.1% 2010‐2017 period). By multivariate analysis, associated with less NRM (HR...
Abstract We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL) receiving hematopoietic cell transplantation (HCT) from a haploidentical (n = 487) or matched unrelated donor (MUD; n 974) between January 2005 and June 2018. Graft-versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy), calcineurin inhibitor (CNI), mycophenolate mofetil (MMF) for haploidentical, CNI MMF methotrexate with/without antithymoglobulin MUDs. Haploidentical...
Hypereosinophilic syndrome (HES) is defined as chronic, unexplained hypereosinophilia with organ involvement. A subset of HES patients presents an interstitial deletion in chromosome 4q12, which leads to the expression imatinib-responsive fusion gene, FIP1L1-PDGFRA. These are diagnosed chronic eosinophilic leukaemia (CEL). We treated seven CEL and patients, six expressed FIP1L1-PDGFRA, imatinib using initial daily doses ranging from 100 400 mg. In a remission maintenance phase, were once...
Background A T-cell clone, thought to be the source of eosinophilopoietic cytokines, identified by clonal rearrangement receptor and presence aberrant immunophenotype in peripheral blood defines lymphocytic variant hypereosinophilic syndrome (L-HES).Design Methods Peripheral samples from 42 patients who satisfied diagnostic criteria for HES were studied polymerase chain reaction according BIOMED-2. The population was assessed flow cytometry. FIP1L1-PDGFRA fusion gene detected nested...
The treatment of patients with multiple myeloma usually includes many drugs including thalidomide, lenalidomide and bortezomib. Lovastatin other inhibitors HMG-CoA reductase demonstrated to exhibit antineoplasmatic proapoptotic properties in numerous vitro studies involving cell lines. We treated 91 relapsed or refractory dexamethasone lovastatin (TDL group, 49 patients) thalidomide (TD 42 patients). A clinical response defined at least 50% reduction monoclonal band has been observed 32% TD...
ABSTRACT Objectives The study evaluated the impact of lifestyle and environmental exposure on etiology multiple myeloma (MM). Methods A multicenter case–control was conducted in 20 hematology centers 5 outpatient clinics Poland. questionnaire to potential risk factors including sociodemographic data, lifestyle, completed. Results total 274 patients with newly diagnosed MM 208 from primary healthcare control group were enrolled study. Regarding sports practiced systematically for at least...
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative approach for many hematologic disorders, and donor leukemia (DCL) remains complication rarely observed after HSCT. The number of reported cases DCL slightly exceeds 100, with acute myeloid (AML) being the most common type. To date, only few chronic lymphocytic (CLL) emerging from cells have been described in literature. Here, we report two CLL origin, which emerged patients HSCT AML. In cases, maintained complete...
Post-transplant lymphoproliferative disorder (PTLD) is a potentially life-threatening complication, often associated with Epstein-Barr virus (EBV) in the early period after hematopoietic stem cell transplantation (HSCT). Clinical manifestations range from localized to disseminated disease. The cornerstone of therapy reduction immunosuppression and/or immunochemotherapy. We report 39-year-old female who developed PTLD presenting as lymphoplasmacytic lymphoma (LPL) hemophagocytic...
Idiopathic hypereosinophilic syndrome (IHES) is characterized by blood hypereosinophilia with no underlying cause and eosinophilia-associated organ dysfunction. Thirty-three patients, 20 female (61%) 13 male (29%), a median age of 56 years at diagnosis (range 16-77 years) were included in the study. The eosinophilia was 7.6 × 10(9)/L percentage eosinophils bone marrow 39.5%. most common clinical manifestations splenomegaly cardiac involvement. Corticosteroids (CS) as monotherapy initiated...
Splenectomy before allogeneic stem cell transplantation (ASCT) for patients with myelofibrosis (MF) remains a matter of debate, and conflicting results have been reported to date. The procedure seems fasten post-transplant hematological recovery, but it does not an impact on survival. role pre-transplant splenic irradiation (SI) is much more difficult evaluate. Forty-four (25 males 19 females) MF at median age 49 years diagnosis (range 14-67) underwent ASCT. outcome was compared between...
We compared severe graft-versus-host-disease (GvHD) free and relapse-free survival other transplantation outcomes of acute myeloid leukemia (AML) patients given bone marrow (BM) without anti-thymocyte globulin (ATG) versus peripheral blood stem cells (PBSC) with ATG after myeloablative conditioning. In the cohort receiving grafts from a human leukocyte antigen (HLA)-matched sibling donor, PBSC (n=1,021) those BM (n=1,633) presented comparable GvHD-free (GRSF)(hazard ratio [HR]=0.9, 95%...
The number of newly diagnosed haematological malignancies in Polish adults and children is about 9,000 a year, which constitutes 5.5% all the country. Adult patients with are treated 42 institutions Poland. scientific educational support for this activity provided under umbrella Society Haematologists Transfusiologists (PTHiT, Polskie Towarzystwo Hematologów i Transfuzjologów ), Leukemia Group (PALG), Lymphoma Research (PLRG), Myeloma Study (PMSG), Consortium (PMC), consultants haematology....
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), number patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) myeloid leukemia (CML) has dramatically decreased. Imatinib was first TKI introduced to clinical arena, predominantly utilized in line setting. In cases insufficient response, resistance, or intolerance, CML can subsequently be treated with either a second third generation TKI. Between 2006 and 2016, we analyzed...